Pharmacogenetics and pharmacogenomics: Adverse drug reactions

Pharmacogenomics

Volumn 9, Issue 10, 2008, Pages 1397-1401

  Jorgensen, Andrea ^a   Alfirevic, Ana ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; CARBAMAZEPINE; CISAPRIDE; CLOZAPINE; CYTOCHROME P450 2C9; FLUCLOXACILLIN; HLA B57 ANTIGEN; ITRACONAZOLE; SILDENAFIL; THIOPURINE METHYLTRANSFERASE; TICLOPIDINE; VIGABATRIN; WARFARIN;

AGRANULOCYTOSIS; BLEEDING; BLUE VISION; CLINICAL LABORATORY; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOTYPE; HUMAN; LIVER TOXICITY; MYOCARDITIS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; STEVENS JOHNSON SYNDROME; THROMBOEMBOLISM; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER; VISUAL FIELD DEFECT;

FORECASTING; GENOME, HUMAN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 55449110807     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.10.1397     Document Type: Conference Paper

References (10)

1. Hirata K, Takagi H, Yamamoto M et al.: Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8, 29-33 (2008).
2. Haas SJ, Hill R, Krum H et al.: Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 30, 47-57 (2007).
3. Killian JG, Kerr K, Lawrence C, Celermajer DS: Myocarditis and cardiomyopathy associated with clozapine. Lancet 354, 1841-1845 (1999).
4. Hughes AR, Spreen WR, Mosteller M et al.: Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. DOI 10.1038/tpj.2008.3 (2008) (Epub ahead of print).
5. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
6. Wadelius M, Chen LY, Lindh JD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood DOI: 10.1182/blood-2008-04-149070 (2008) (Epub ahead of print).
7. Merrick BA: The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. Brief Funct. Genomic Proteomic 7, 35-49 (2008).
8. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
9. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R: Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 7, 325-332 (2007).
10. Owen RP, Altman RB, Klein TE: PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum. Mut. 29(4), 456-460 (2008).